231 filings
Page 3 of 12
424B5
t316dm3hwnef
3 Feb 21
Prospectus supplement for primary offering
4:20pm
EFFECT
jdo0dz8af7n vfv3xbck
3 Feb 21
Notice of effectiveness
12:15am
8-K
h5gue
1 Feb 21
Departure of Directors or Certain Officers
4:17pm
CORRESP
lqa im0bal9xj8mjd
28 Jan 21
Correspondence with SEC
12:00am
UPLOAD
e88ooyn5rj469c
22 Jan 21
Letter from SEC
12:00am
8-K
m6k47yy xbmk6w2keew
11 Dec 20
Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody
4:05pm
8-K
gjrxr
7 Dec 20
Departure of Directors or Certain Officers
9:02am
8-K
hbm8g 1yszue7w76src
25 Nov 20
Other Events
4:11pm
8-K
4pes6czoc4ih3bcc9p
20 Nov 20
Other Events
5:19pm
8-K
iiyzesw4kkf bd6ddzi
9 Nov 20
Kindred Biosciences Announces Third Quarter 2020 Financial Results
4:08pm
8-K
wm8m9qje
7 Oct 20
Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
8:20am
8-K
fvgd gdhom
16 Sep 20
Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody
8:12am
8-K
oiqpkrzzv3e
5 Aug 20
Kindred Biosciences Announces Second Quarter 2020 Financial Results
4:09pm
S-8
n6zcp16xc6vx0fc
24 Jul 20
Registration of securities for employees
4:06pm
8-K
r59r113
17 Jun 20
Departure of Directors or Certain Officers
4:04pm
8-K
z97zm72
8 Jun 20
Kindred Biosciences Announces Plan to Strengthen Its Strategic Position
4:19pm
8-K
o25zj35qsxdbe
20 May 20
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
8:01am